Evidence map›Paper›PMID 35171296›Full record

ReviewNicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco2022

Bridging: Accelerating Regulatory Acceptance of Reduced-Risk Tobacco and Nicotine Products.

Marianna Gaca, Justine Williamson, Helena Digard, Louise Adams, Lauren Hawkridge, Christopher Proctor

Abstract readReview
In one paragraph

Review in Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. AnCurrent research in toxicology · 2024
    Article
  5. Review
  6. Do Tobacco Companies Have an Incentive to Promote "Harm Reduction" Products?: The Role of Competition.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2023
    Article
  7. A Decision-Theoretic Public Health Framework for Heated Tobacco and Nicotine Vaping Products.International journal of environmental research and public health · 2022
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Marianna GacaBritish American Tobacco (Holdings) Ltd, Globe House, 4 Temple Place, London WC2R 2PG, UK.ORCID 0000-0002-5881-0706
Justine WilliamsonBritish American Tobacco (Holdings) Ltd, Globe House, 4 Temple Place, London WC2R 2PG, UK.
Helena DigardResearch and Development, British American Tobacco (Investments) Ltd, Regent's Park Road, Southampton SO15 8TL, UK.
Louise AdamsResearch and Development, British American Tobacco (Investments) Ltd, Regent's Park Road, Southampton SO15 8TL, UK.
Lauren HawkridgeResearch and Development, British American Tobacco (Investments) Ltd, Regent's Park Road, Southampton SO15 8TL, UK.
Christopher ProctorDoctorProctorScience Ltd, 157 Cavendish Meads, Ascot, Berkshire SL5 9TG, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe number and variety of alternative tobacco and nicotine products that can potentially provide reduced-risk choices for cigarette smokers who switch completely to such products instead of continued smoking have grown substantially in the past decade. Innovation and choice are likely to improve the prospects of smokers making the switch, but this provides challenges to regulators and manufacturers to ensure that changes to regulations and products promote and do not hinder contributions to tobacco harm reduction. AIMS AND

methodsThis paper looks at where bridging data sets for tobacco heating products, closed system vaping products, and oral nicotine products might enable innovation while protecting the interests of consumers.

resultsWe review product data from chemical studies and a toxicological study showing how bridging can be applied and consider what product development changes might allow bridging from existing datasets or trigger the need for new ones.

conclusionsBridging across specific product ranges can increase the speed of innovation, foster competition, and limit the burden of assessment for regulators while maintaining product safety and quality. IMPLICATIONS: Bridging partial data sets is an established practice within other industries, that aims to improve efficiency with regulatory approvals, accepts natural product variation, and supports product innovation. We review product data from chemical studies and a toxicological study showing how bridging can be applied and consider what product development changes might allow bridging from existing datasets or trigger the need for new ones. This in turn can increase the speed of innovation, foster competition, and limit the burden of assessment for regulators while maintaining product safety and quality.

Indexed as

Electronic Nicotine Delivery SystemsSmoking CessationTobacco ProductsVapingHumansNicotineNicotine

Identifiers

PMID35171296
PMCPMC9356683

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.